Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Disaggregation of Income Statement Expenses

This following table presents segment operation results for the three months ended March 31, 2025 and 2024:

	Three Months Ended March 31,
	2025		2024
Operating expenses:
Research and development - external costs (1)	$	103,806	$	69,637
Research and development - internal costs (2)	44,328		24,950
General and administrative	32,659		19,885
Total operating expenses	$	180,793	$	114,472
Total other income, net	$	40,075	$	19,452
Net loss	$	140,718	$	95,020

____________________________________________________________

(1)Research and development - external costs consist of product manufacturing costs, clinical costs, research and development consumables, lab supplies and equipment, facility and allocated costs, and other external costs.

(2)Research and development - internal costs consist of internal employee costs including stock-based compensation expenses.